Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 27;17:85. doi: 10.1186/s13024-022-00578-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Neuropathologic evaluation of regional digital pathology measures of tau and amyloid-β pathology in comparison to plasma p-tau181 and p-tau217 in parietal cortex. Utilizing the same epitope to immunohistochemically evaluate regional tau pathology in inferior parietal cortex, tau burden measures were compared to p-tau plasma levels (A, C). pT181 tau burden measures strongly associated with p-tau181 plasma levels (A), with the association even stronger between pT217 and p-tau217 plasma levels (C). Digital pathology measures of amyloid-β (6F/3D) were additionally compared to plasma p-tau levels (B, D). Amyloid-β burden strongly associated with ptau-181 (B). The strongest overall association of digital pathology measures was observed between amyloid-β (6F/3D) and p-tau217 (D). P-tau181 (A-B) and p-tau217 (C-D) were examined across all individuals studied with AD shown as triangles, PA as diamonds, and primary tauopathies as circles. Spearman correlation and corresponding significance displayed. Case with high creatinine was not included. Trendline with 95% confidence interval was computed from a linear model. Data presented are Spearman correlation and corresponding significance. Acronyms: AD Alzheimer’s disease, AGD argyrophilic grain disease, MSD meso scale discovery, PA pathological aging, PART primary age-related tauopathy, PSP progressive supranuclear palsy, p-tau phosphorylated tau for plasma levels, pT phosphorylated threonine for immunohistochemical measures of tau